PCOS overlooked as pharmaceutical companies gain from women’s infertility

Fertility Rates: A Growing Concern

The drop in fertility rates has caught everyone’s attention for several understandable reasons. In the U.S., the fertility rate has fallen to 1.6 births per woman—well below the replacement level of 2.1.

Earlier this year, the Trump administration suggested a plan to counteract this trend—a $5,000 single “baby bonus,” along with expanded funding for IVF and fertility education. Yet, while it’s crucial to consider the high costs associated with raising children, it’s evident that deeper issues hinge on women’s fertility.

America needs to prioritize reproductive health if it’s serious about reversing demographic decline.

Many American women have been dealing with infertility for a long time. Doctors often disregard underlying conditions when prescribing treatments, which tends to focus solely on medications rather than on understanding the root causes. Take, for instance, the use of birth control pills; many practitioners opt for quick fixes rather than investigating environmental, dietary, or lifestyle changes. This trend is particularly noticeable with conditions like polycystic ovarian syndrome.

Underdiagnosed and Underfunded

Polycystic ovarian syndrome (PCOS) is a significant contributor to anovulation and infertility, affecting up to 13% of women of reproductive age. It results in irregular ovulation and elevated androgen levels, leading to a higher risk of miscarriage. Alarmingly, around 70% of those affected remain undiagnosed.

Funding for PCOS research is alarmingly low. Between 2016 and 2022, the funding averaged about $31.8 million annually, which pales in comparison to the $262 million allocated for rheumatoid arthritis and $420 million for lupus. The morbidity of PCOS resembles that of these conditions, yet funding doesn’t reflect that reality. In 2022, the NIH reported only $9.5 million for PCOS, a stark contrast to its significant economic burden—estimated at $15 billion annually in the U.S.

Women as Economic Resources

Current approaches to treating PCOS suggest a focus on long-term medication and costly IVF procedures rather than on lifestyle changes or preventive measures. Conversations about nutrition and environmental health often land in the “anti-science” category. Yet the reality is that PCOS is manageable often through lifestyle changes alone.

PCOS can have genetic components but is also closely linked to insulin resistance, obesity, and various environmental factors, like family history of type II diabetes. Improving outcomes can often come from better nutrition, exercise, and weight management.

Even a modest weight loss—say 5% to 10%—in overweight women can restore ovulation. However, unfortunately, guidance that avoids invasive methods is sometimes dismissed as body shaming.

Women facing the pressures of infertility often find themselves pouring money into costly procedures, rather than receiving comprehensive, targeted advice for managing their health.

Addressing a Complicated Issue

Women’s fertility has become a contentious issue politically, making it harder to garner the necessary research and funding for real solutions. Instead, women often end up as sources of revenue for the healthcare industry, which benefits from repetitive treatments and prescriptions. The underlying issues that could prevent infertility are generally overlooked.

Challenging the status quo in fertility treatments is often branded as “anti-science.” This mindset is a considerable barrier. The need of the hour is to address the core issues around reproductive health. If America is genuinely invested in reversing its demographic decline, it must start with in-depth approaches to fertility and reproductive wellness.